DE60309300D1 - Nanopartikelzusammensetzungen von angiogeneseinhibitoren - Google Patents
Nanopartikelzusammensetzungen von angiogeneseinhibitorenInfo
- Publication number
- DE60309300D1 DE60309300D1 DE60309300T DE60309300T DE60309300D1 DE 60309300 D1 DE60309300 D1 DE 60309300D1 DE 60309300 T DE60309300 T DE 60309300T DE 60309300 T DE60309300 T DE 60309300T DE 60309300 D1 DE60309300 D1 DE 60309300D1
- Authority
- DE
- Germany
- Prior art keywords
- nanoparticle compositions
- angiogenic inhibitors
- compositions
- angiogenic
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36554002P | 2002-03-20 | 2002-03-20 | |
| US365540P | 2002-03-20 | ||
| US36654202P | 2002-03-25 | 2002-03-25 | |
| US366542P | 2002-03-25 | ||
| PCT/US2003/008546 WO2003080027A1 (en) | 2002-03-20 | 2003-03-20 | Nanoparticulate compositions of angiogenesis inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE60309300D1 true DE60309300D1 (de) | 2006-12-07 |
| DE60309300T2 DE60309300T2 (de) | 2007-05-10 |
| DE60309300T3 DE60309300T3 (de) | 2011-02-24 |
Family
ID=28457111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60309300T Expired - Lifetime DE60309300T3 (de) | 2002-03-20 | 2003-03-20 | Nanopartikelzusammensetzungen von angiogeneseinhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US20040033267A1 (de) |
| EP (1) | EP1490030B2 (de) |
| JP (2) | JP4842514B2 (de) |
| AT (1) | ATE343376T1 (de) |
| AU (1) | AU2003230691A1 (de) |
| CA (1) | CA2479665C (de) |
| DE (1) | DE60309300T3 (de) |
| WO (1) | WO2003080027A1 (de) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
| JP2002525311A (ja) * | 1998-10-01 | 2002-08-13 | エラン ファーマ インターナショナル，リミティド | 徐放性ナノ粒子組成物 |
| US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
| US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| WO2003030872A2 (en) * | 2001-10-12 | 2003-04-17 | Elan Pharma International Ltd. | Compositions having a combination of particles for immediate release and for controlled release |
| ATE464880T1 (de) | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
| US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
| EP1800666A1 (de) * | 2002-03-20 | 2007-06-27 | Elan Pharma International Limited | Nanopartikelzusammensetzungen von Angiogeneseinhibitoren |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| WO2003080027A1 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
| WO2005016364A1 (en) * | 2003-08-14 | 2005-02-24 | Guthy-Renker Corporation | Skin care composition including hexapeptide complexes and methods of their manufacture |
| ES2366646T3 (es) * | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. |
| CA2558014A1 (en) * | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Antiangiogenic agents |
| US20070004689A1 (en) * | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
| WO2005096271A1 (ja) * | 2004-03-30 | 2005-10-13 | Pioneer Corporation | 音声認識装置及び音声認識方法 |
| DE102004022927A1 (de) * | 2004-05-10 | 2005-12-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| GB0418791D0 (en) * | 2004-08-23 | 2004-09-22 | Glaxo Group Ltd | Novel process |
| US20060116404A1 (en) * | 2004-09-24 | 2006-06-01 | Gary Robinson | CAI-based systems and methods for the localized treatment of ocular and other diseases |
| CA2581652C (en) * | 2004-09-27 | 2013-10-29 | Valentis, Inc. | Formulations and methods for treatment of inflammatory diseases |
| US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| CN101160118A (zh) * | 2005-02-24 | 2008-04-09 | 依兰药物国际有限公司 | 多西紫杉醇或其类似物的纳米微粒制剂 |
| EP1855651A4 (de) * | 2005-03-03 | 2011-06-15 | Elan Pharma Int Ltd | Nanopartikelzusammensetzungen heterocyclischer amidderivate |
| US8309133B2 (en) * | 2005-04-12 | 2012-11-13 | Alkermes Pharma Ireland Limited | Nanoparticulate quinazoline derivative formulations |
| AU2006239811B2 (en) * | 2005-04-25 | 2012-02-02 | Enterin, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| KR20080008403A (ko) * | 2005-05-10 | 2008-01-23 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 클로피도그렐 제제 |
| WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
| KR20080017065A (ko) * | 2005-06-03 | 2008-02-25 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 아세트아미노펜 제제 |
| WO2006133046A2 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
| US9089619B2 (en) * | 2005-06-06 | 2015-07-28 | University Of Kentucky | Hybrid nanocrystals for treatment and bioimaging of disease |
| CA2612994A1 (en) | 2005-06-08 | 2006-12-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cefditoren |
| JP2008543766A (ja) * | 2005-06-09 | 2008-12-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子エバスチン製剤 |
| MX2007015882A (es) * | 2005-06-13 | 2008-03-04 | Elan Pharma Int Ltd | Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina. |
| US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
| CA2612384A1 (en) * | 2005-06-15 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate azelnidipine formulations |
| EP1904041A2 (de) * | 2005-07-07 | 2008-04-02 | Elan Pharma International Limited | Nanopartikuläre clarithromycinformulierung |
| JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
| CA2622758A1 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| US20090317475A1 (en) * | 2006-01-03 | 2009-12-24 | Beardsley Robert A | Combination antitumor therapies |
| BRPI0712130A2 (pt) | 2006-05-30 | 2012-01-17 | Elan Pharma Int Ltd | formulações de posaconazol em nanopartìculas |
| TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
| AU2007272501A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Pharma International Limited | Nanoparticulate formulations of modafinil |
| WO2008035246A2 (en) | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
| US9132071B2 (en) * | 2006-07-28 | 2015-09-15 | Santen Sas | Compositions containing quaternary ammonium compounds |
| EA015304B1 (ru) | 2006-08-03 | 2011-06-30 | Нитек Фарма Аг | Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением |
| WO2008094665A1 (en) * | 2007-01-31 | 2008-08-07 | Entremed, Inc. | Method of treating amyloidosis mediated diseases |
| HU227970B1 (en) * | 2007-07-10 | 2012-07-30 | Egis Gyogyszergyar Nyrt | Pharmaceutical compositions containing silicones of high volatility |
| WO2009061428A1 (en) | 2007-11-06 | 2009-05-14 | Kline Ellis L | Compositions and methods for treating parkinson's disease and related disorders |
| CA2715422A1 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharma International Limited | Compositions for site-specific delivery of imatinib and methods of use |
| CA2725203A1 (en) * | 2008-05-22 | 2009-11-26 | Larry Mark Weisenthal | Efficient wellbeing assessment and improved treatment protocol |
| CN102300571A (zh) * | 2008-12-01 | 2011-12-28 | 英沃兹科医疗有限公司 | 包括肾素—血管紧张素醛固酮系统抑制剂和硫辛酸化合物的组合物，及其用于肾素—血管紧张素醛固酮系统相关病症的治疗 |
| WO2010084188A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
| HUE032426T2 (en) | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
| US8623416B2 (en) * | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| AU2011309872B2 (en) * | 2010-10-01 | 2014-09-04 | Cipla Limited | Pharmaceutical composition comprising deferasirox |
| WO2013074988A1 (en) | 2011-11-17 | 2013-05-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
| CA2914782C (en) * | 2012-06-21 | 2021-05-25 | Phosphorex, Inc. | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
| US10045965B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| AU2015280412B2 (en) | 2014-06-26 | 2018-07-26 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| TW201642837A (zh) | 2015-03-24 | 2016-12-16 | Kyowa Hakko Kirin Co Ltd | 含有核酸之脂質奈米粒子 |
| WO2016187767A1 (en) * | 2015-05-25 | 2016-12-01 | Hutchison Medipharma Limited | Pharmaceutical compositions and use thereof |
| US9763892B2 (en) | 2015-06-01 | 2017-09-19 | Autotelic Llc | Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods |
| US10751319B2 (en) | 2015-06-04 | 2020-08-25 | Crititech, Inc. | Collection device and methods for use |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| CA2998483C (en) | 2015-09-16 | 2022-09-06 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| HUP1500618A2 (en) | 2015-12-16 | 2017-06-28 | Druggability Tech Ip Holdco Ltd | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them |
| CN105748425A (zh) * | 2016-02-29 | 2016-07-13 | 北京颐诺赛医药科技有限公司 | 2-甲氧雌二醇增溶药物制剂 |
| WO2017176628A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| ES2955884T3 (es) | 2017-03-15 | 2023-12-07 | Dfb Soria Llc | Terapia tópica para el tratamiento de malignidades de la piel con nanoparticulas de taxanos |
| RU2019134145A (ru) | 2017-06-09 | 2021-07-09 | Крититек, Инк. | Лечение эпителиальных кист путем внутрикистозной инъекции противоопухолевых частиц |
| KR20210118468A (ko) | 2017-06-14 | 2021-09-30 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| EP3691631A1 (de) | 2017-10-03 | 2020-08-12 | Crititech, Inc. | Lokale verabreichung von antineoplastischen partikeln in kombination mit systemischer abgabe von immunotherapeutischen mitteln zur behandlung von krebs |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
| WO2019153088A1 (en) * | 2018-02-09 | 2019-08-15 | Neutrisci International Inc. | Compositions comprising co-crystals of stilbenoids and cannabinoids |
| JP7372252B2 (ja) | 2018-03-16 | 2023-10-31 | ディーエフビー ソリア リミテッド ライアビリティ カンパニー | タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2671750A (en) * | 1950-09-19 | 1954-03-09 | Merck & Co Inc | Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same |
| US2871750A (en) * | 1953-06-08 | 1959-02-03 | Northrop Aircraft Inc | Explosively released nut |
| US3269798A (en) * | 1962-01-26 | 1966-08-30 | Preston John Miles | Stabilized phosphoric acid |
| BE637389A (de) * | 1962-09-13 | |||
| BE629985A (de) * | 1962-11-29 | |||
| US3536074A (en) * | 1968-03-29 | 1970-10-27 | Alfred Aufhauser | Oral administration of a pill,tablet or capsule |
| US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
| US3692532A (en) * | 1970-10-27 | 1972-09-19 | David R Shenkenberg | Milk-fruit juice beverage and process for preparing same |
| JPS4932056B1 (de) * | 1970-12-22 | 1974-08-27 | ||
| US4073943A (en) * | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
| US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
| US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
| DK143689C (da) * | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
| US4534899A (en) * | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
| US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
| US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
| US4917816A (en) * | 1984-01-03 | 1990-04-17 | Abco Industries, Inc. | Stabilized peroxide compositions and process for producing same |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
| US4663364A (en) * | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
| US4639364A (en) * | 1984-11-14 | 1987-01-27 | Mallinckrodt, Inc. | Methods and compositions for enhancing magnetic resonance imaging |
| US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| JPS62185013A (ja) * | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | 易吸収性医薬組成物 |
| EP0262560A3 (de) * | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl-Harnstoff-Verbindungen |
| EP0264904A3 (de) * | 1986-10-23 | 1988-08-17 | Ishihara Sangyo Kaisha, Ltd. | Benzoylharnstoff-Derivate enthaltende Arzneimittel |
| FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
| FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
| US5006650A (en) * | 1987-02-11 | 1991-04-09 | The Upjohn Company | Novel N-1 substituted beta-lactams as antibiotics |
| US5723147A (en) * | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| EP0357604A1 (de) * | 1987-02-27 | 1990-03-14 | The Upjohn Company | Pyridon-carbonsäure oder säurederivat enthaltendes beta-lactame-antibiotikum |
| US5015737A (en) * | 1987-07-22 | 1991-05-14 | The Upjohn Company | Therapeutically useful beta-lactams |
| US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
| US4929446A (en) * | 1988-04-19 | 1990-05-29 | American Cyanamid Company | Unit dosage form |
| JP2661709B2 (ja) * | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | 高活性な農薬水和剤の製法 |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US4951673A (en) * | 1988-08-19 | 1990-08-28 | Alliance Pharmaceutical Corp. | Magnetic resonance imaging with perfluorocarbon hydrides |
| US5041292A (en) * | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| JPH02196719A (ja) * | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | 粉末状医薬組成物 |
| US5114703A (en) * | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
| GB8914060D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| SE464743B (sv) * | 1989-06-21 | 1991-06-10 | Ytkemiska Inst | Foerfarande foer framstaellning av laekemedelspartiklar |
| US5116599A (en) * | 1989-07-31 | 1992-05-26 | Johns Hopkins Univ. | Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri |
| FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
| JP2687245B2 (ja) * | 1989-09-29 | 1997-12-08 | 富士写真フイルム株式会社 | 磁気記録媒体の製造方法 |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| JPH0410856A (ja) * | 1990-04-27 | 1992-01-16 | Hitachi Koki Co Ltd | レーザ記録装置 |
| US5124388A (en) * | 1990-05-07 | 1992-06-23 | Eastman Kodak Company | Films and containers of heat resistant copolyesters |
| US5110606A (en) * | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
| US5552160A (en) † | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5143716A (en) * | 1991-02-01 | 1992-09-01 | Unger Evan C | Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region |
| US5416071A (en) * | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
| US5434143A (en) * | 1991-05-10 | 1995-07-18 | Boron Biologicals, Inc. | Pharmaceutical compositions comprising phosphite-borane compounds |
| GB9111580D0 (en) * | 1991-05-30 | 1991-07-24 | Wellcome Found | Nucleoside derivative |
| WO1993000933A1 (en) * | 1991-07-05 | 1993-01-21 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
| JP2573444B2 (ja) * | 1991-09-26 | 1997-01-22 | 株式会社日立製作所 | 内燃機関用点火装置 |
| US5442062A (en) * | 1991-10-24 | 1995-08-15 | The Upjohn Company | Imidazole derivatives and pharmaceutical compositions containing the same |
| WO1993018751A1 (en) * | 1992-03-23 | 1993-09-30 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
| US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| FR2698560B1 (fr) * | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
| US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
| US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| CA2153686A1 (en) * | 1993-01-11 | 1994-07-21 | Michihiko Kuwano | Angiogenesis inhibitor and novel compound |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| CN1245156C (zh) * | 1993-02-22 | 2006-03-15 | 美国生物科学有限公司 | 用于体内传送生物制品的方法及用于该方法的组合物 |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5916596A (en) † | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
| US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5731334A (en) * | 1994-01-11 | 1998-03-24 | The Scripps Research Institute | Method for treating cancer using taxoid onium salt prodrugs |
| DE69533569T2 (de) * | 1994-03-07 | 2006-01-05 | Dendritic Nanotechnologies, Inc., Mt. Pleasant | Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material |
| GB9405593D0 (en) * | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
| US5731355A (en) * | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
| US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
| US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
| US5888765A (en) * | 1995-06-23 | 1999-03-30 | President And Fellows Of Harvard College | Endothelial-cell specific promoter |
| GB9515214D0 (en) * | 1995-07-25 | 1995-09-20 | Univ Strathclyde | Plant extracts |
| US5720052A (en) * | 1995-08-30 | 1998-02-24 | Walker; Fern Lisa | Neck protection device |
| KR19990076988A (ko) * | 1996-01-03 | 1999-10-25 | 피터 기딩스 | 머틸린의 카르바모일옥시 유도체 및 항균제로서의 이들의 용도 |
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US5637625A (en) * | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
| EP0818450B1 (de) * | 1996-07-08 | 2003-01-15 | Ciba SC Holding AG | Triazinderivate als UV-Filter in Sonnenschutzmitteln |
| MX9801835A (es) * | 1996-07-08 | 1998-08-30 | Mendell Co Inc Edward | Matriz de liberacion sostenida para medicamentos insolubles de dosis altas. |
| US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| IL128632A (en) * | 1996-08-22 | 2003-03-12 | Rtp Pharma Corp | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
| US5750737A (en) * | 1996-09-25 | 1998-05-12 | Sisti; Nicholas J. | Method for paclitaxel synthesis |
| IN186315B (de) * | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd | |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6051563A (en) * | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US20020002294A1 (en) * | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
| WO1999044987A1 (en) * | 1998-03-05 | 1999-09-10 | Agouron Pharmaceuticals, Inc. | NON-PEPTIDE GnRH AGENTS |
| US6228985B1 (en) * | 1998-05-21 | 2001-05-08 | Schering Corporation | Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents |
| JP4693238B2 (ja) * | 1998-06-19 | 2011-06-01 | オバン・エナジー・リミテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
| US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| JP2002525311A (ja) * | 1998-10-01 | 2002-08-13 | エラン ファーマ インターナショナル，リミティド | 徐放性ナノ粒子組成物 |
| US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
| US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
| US6028108A (en) * | 1998-10-22 | 2000-02-22 | America Home Products Corporation | Propofol composition comprising pentetate |
| US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
| US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6969529B2 (en) * | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| SA99191255B1 (ar) † | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| US6225311B1 (en) * | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| US6177477B1 (en) * | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6100302A (en) * | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
| JP3865029B2 (ja) * | 1999-05-11 | 2007-01-10 | 株式会社日立プラズマパテントライセンシング | プラズマディスプレイパネル |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB9913536D0 (en) * | 1999-06-10 | 1999-08-11 | Sterix Ltd | Use |
| US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| AU2001261425A1 (en) * | 2000-05-12 | 2001-11-26 | Lindon Products, Inc. | Cases for medication delivery devices |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US20040156872A1 (en) * | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
| US6362234B1 (en) * | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
| US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
| US6399087B1 (en) * | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| ATE464880T1 (de) * | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
| US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
| WO2003080027A1 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
-
2003
- 2003-03-20 WO PCT/US2003/008546 patent/WO2003080027A1/en active IP Right Grant
- 2003-03-20 CA CA2479665A patent/CA2479665C/en not_active Expired - Fee Related
- 2003-03-20 EP EP03723781A patent/EP1490030B2/de not_active Expired - Lifetime
- 2003-03-20 AU AU2003230691A patent/AU2003230691A1/en not_active Abandoned
- 2003-03-20 AT AT03723781T patent/ATE343376T1/de not_active IP Right Cessation
- 2003-03-20 DE DE60309300T patent/DE60309300T3/de not_active Expired - Lifetime
- 2003-03-20 US US10/392,403 patent/US20040033267A1/en not_active Abandoned
- 2003-03-20 JP JP2003577857A patent/JP4842514B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-30 US US11/928,289 patent/US20080226732A1/en not_active Abandoned
- 2007-10-30 US US11/928,250 patent/US20080050461A1/en not_active Abandoned
- 2007-10-30 US US11/928,278 patent/US20080107741A1/en not_active Abandoned
-
2008
- 2008-05-09 US US12/117,982 patent/US20080279949A1/en not_active Abandoned
-
2009
- 2009-11-24 JP JP2009266089A patent/JP2010077146A/ja not_active Withdrawn
-
2010
- 2010-08-27 US US12/870,749 patent/US20100329976A1/en not_active Abandoned
- 2010-08-27 US US12/870,745 patent/US20100322853A1/en not_active Abandoned
- 2010-08-27 US US12/870,722 patent/US20100322852A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005530712A (ja) | 2005-10-13 |
| WO2003080027A1 (en) | 2003-10-02 |
| EP1490030B2 (de) | 2010-07-14 |
| DE60309300T3 (de) | 2011-02-24 |
| US20080226732A1 (en) | 2008-09-18 |
| JP2010077146A (ja) | 2010-04-08 |
| AU2003230691A1 (en) | 2003-10-08 |
| US20100322852A1 (en) | 2010-12-23 |
| US20100329976A1 (en) | 2010-12-30 |
| EP1490030B1 (de) | 2006-10-25 |
| ATE343376T1 (de) | 2006-11-15 |
| CA2479665A1 (en) | 2003-10-02 |
| US20080107741A1 (en) | 2008-05-08 |
| US20040033267A1 (en) | 2004-02-19 |
| JP4842514B2 (ja) | 2011-12-21 |
| US20080050461A1 (en) | 2008-02-28 |
| US20100322853A1 (en) | 2010-12-23 |
| CA2479665C (en) | 2011-08-30 |
| DE60309300T2 (de) | 2007-05-10 |
| US20080279949A1 (en) | 2008-11-13 |
| EP1490030A1 (de) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60309300D1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
| ATE385777T1 (de) | Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren | |
| CY1107810T1 (el) | Συνθεσεις οι οποιες εχουν ενα συνδυασμο χαρακτηριστικων αμεσης απελευθερωσης και ελεγχομενης απελευθερωσης | |
| ATE457718T1 (de) | Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator | |
| DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
| MX2010009866A (es) | Composiciones de inhibidores de angiogenesis en nanoparticulas. | |
| SG161203A1 (en) | Nanoparticulate tacrolimus formulations | |
| DE60325718D1 (de) | Nystatin-nanopartikelzusammensetzungen | |
| AR040110A1 (es) | Formulaciones de fibrato en nanoparticulas | |
| DE60001219T2 (de) | Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen | |
| EE200300440A (et) | Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks | |
| CY1113036T1 (el) | Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης | |
| CY1110949T1 (el) | Σταθεροποιημενες με πηκτωμα συνθεσεις νανοσωματιδιακων δραστικων παραγοντων | |
| BRPI0518772A2 (pt) | formulaÇÕes de benzotiofeno em nanopartÍcula | |
| ATE318295T1 (de) | Nanopartikuläre zubereitung | |
| NO20076588L (no) | Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring | |
| DE60231082D1 (de) | Nanopartikelzusammensetzungen enthaltend fenofibrat | |
| ATE364370T1 (de) | Kosmetische und dermatologische zusammensetzung enthaltend ein n-acylaminoamid-derivat und einen metalloproteinase-inhibitor | |
| WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
| WO2003013455A3 (de) | Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und latexpartikeln | |
| EP1938803A3 (de) | Formulierungen mit Nanoteilchen-Meloxican | |
| DE50001383D1 (de) | Kosmetische oder pharmazeutische verwendung von nanoskaligen metallseifen | |
| WO2005027832A3 (en) | Edta containing compositions and uses thereof | |
| ECSP972065A (es) | Benzotiofenos, formulaciones que los contienen y metodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8366 | Restricted maintained after opposition proceedings |